--- title: "AZD6234: AstraZeneca's Selective Amylin Agonist Bets on a Gentler Path to Weight Loss - and a Partner in AZD9550 (September 21, 2026) | PepTracker Pro Blog" url: https://peptrackerpro.com/blog/azd6234-astrazeneca-long-acting-selective-amylin-receptor-agonist-sara-pramlintide-analog-amy3r-obesity-overweight-once-weekly-subcutaneous-azd9550-glp1-glucagon-dual-agonist-combination-factorial-nct06862791-fat-selective-weight-loss-phase-2-september-21-2026 description: "AZD6234 is AstraZeneca's once-weekly amylin agonist, engineered to trigger fat-selective weight loss with less nausea than GLP-1 drugs - and it's being tested both alone and paired with the GLP-1/glucagon dual agonist AZD9550. Here's what the preclinical and early-clinical data actually show, and where the open questions are." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) Research & Compounds Research & Compounds # AZD6234: AstraZeneca's Selective Amylin Agonist Bets on a Gentler Path to Weight Loss - and a Partner in AZD9550 (September 21, 2026) PepTracker Pro Research Team September 21, 2026 9 min read ## Table of Contents - What AZD6234 is, in one line - Why 'selective' is the whole pitch - The preclinical case: fat-selective loss, less nausea signaling - Where AZD6234 is in the clinic - The AZD9550 combination: amylin meets an incretin backbone - How it fits the crowded amylin field - What to watch, and the bottom line ## What AZD6234 is, in one line AZD6234 is an investigational, once-weekly amylin drug from AstraZeneca designed to help people with obesity or overweight lose weight - and it belongs to the class that many in the field now think will define the next chapter of obesity medicine after GLP-1. Amylin is a natural hormone released from the pancreas alongside insulin; it tells the brain you are full, slows how fast the stomach empties, and reduces how much you eat. AZD6234 is built to mimic that hormone in a long-acting form, and AstraZeneca describes it specifically as a 'selective amylin receptor agonist,' or SARA - a label that turns out to matter, as the next section explains. It is given as a subcutaneous injection and is currently in Phase 2 testing. It is not approved by the FDA or any regulator, and it is available only through clinical trials. ## Why 'selective' is the whole pitch Amylin receptors are built from a calcitonin receptor (CTR) joined to a small helper protein (a RAMP), and different amylin-based drugs hit the amylin receptor and the plain calcitonin receptor to different degrees. AstraZeneca engineered AZD6234 as a synthetic, long-acting analog of pramlintide - the first-generation, short-acting amylin drug - and tuned its balance of activity so that its amylin-receptor (AMY3R) versus calcitonin-receptor selectivity matches that of the natural hormone. In plain terms: it is a highly potent amylin-receptor agonist that behaves more like real amylin than like a broad calcitonin-family drug. That is the difference between a 'selective' amylin agonist such as AZD6234, petrelintide or eloralintide and a 'dual amylin and calcitonin receptor agonist' (DACRA) such as cagrilintide. The bet behind selectivity is that you can keep the appetite-suppressing, weight-lowering benefit while dialing down the parts of the profile that drive nausea and other side effects. ## The preclinical case: fat-selective loss, less nausea signaling Most of what is public about AZD6234 so far comes from animal studies AstraZeneca presented at scientific meetings in 2025. In rodent models, AZD6234 produced weight loss mainly by reducing food intake, and - importantly - it favored the loss of fat mass while sparing lean (muscle) mass, an outcome that matters because preserving muscle during weight loss is a growing priority for the whole field. In head-to-head aversion models (the preclinical proxy for nausea), AZD6234 showed a 'preferential profile,' meaning less aversive signaling than either a DACRA or a GLP-1 receptor agonist. And in a study presented at the American Diabetes Association 2025 meeting (abstract 88-OR), adding AZD6234 to the GLP-1 drug semaglutide produced greater body-weight and fat-mass loss in diet-induced obese rats than either drug alone. Preclinical results do not guarantee human results, but together they frame AZD6234's two-part thesis: gentler tolerability, and a natural partner for incretin drugs. ## Where AZD6234 is in the clinic AZD6234 has cleared a Phase 1 first-in-human study, where it was reported to be well tolerated in healthy participants with no deaths and no serious adverse events - enough to move it into Phase 2. The lead Phase 2b obesity study (NCT06862791, AstraZeneca code D8460C00004) is a global, randomized, double-blind, placebo-controlled trial of roughly 360 adults who have obesity or overweight plus at least one weight-related condition - high blood pressure, abnormal cholesterol, or obstructive sleep apnea - run across about 60 sites in around 7 countries, with participants in the study for approximately 47 weeks. What makes the design notable is that it is a 'reduced factorial': it tests AZD6234 on its own, AstraZeneca's GLP-1/glucagon dual agonist AZD9550 on its own, the two combined, and placebo, all in one trial. ## The AZD9550 combination: amylin meets an incretin backbone AZD6234 is not being developed only as a solo drug. AstraZeneca is pairing it with AZD9550, a dual glucagon and GLP-1 receptor agonist, in both a safety study (NCT06151964) and the factorial Phase 2b trial above. The logic is mechanistic complementarity: GLP-1 and glucagon agonism drive appetite suppression and energy expenditure through incretin pathways, while amylin adds a separate satiety and gastric-emptying lever. If the preclinical hint that amylin plus an incretin delivers additive, fat-selective weight loss holds up in people, an AZD6234 + AZD9550 regimen could aim at deeper, higher-quality weight loss than either mechanism alone - and the single factorial trial is an efficient way to read out monotherapy and combination effects side by side. AZD6234 is also being studied added on top of existing GLP-1 therapy in people with type 2 diabetes and obesity (NCT06851858). ## How it fits the crowded amylin field The amylin space has become one of the most competitive in metabolic medicine. Zealand Pharma and Roche's petrelintide is a selective amylin monotherapy that posted double-digit weight loss with a 'placebo-like' safety profile in Phase 2; Eli Lilly's eloralintide is another selective amylin agonist with striking early efficacy and low GI side effects; Novo Nordisk's cagrilintide (a DACRA) anchors the CagriSema combination and its amycretin GLP-1/amylin molecule is heading into Phase 3. Against that backdrop, AZD6234's differentiation is less about being first and more about AstraZeneca's combination strategy and its emphasis on fat-selective, muscle-sparing weight loss with a tolerability edge. The catch is that, as of September 2026, AstraZeneca has not publicly released detailed human efficacy numbers for AZD6234 - so its real-world standing against petrelintide, eloralintide and cagrilintide is still to be proven. ## What to watch, and the bottom line The key things to watch are the Phase 2b readouts: how much weight AZD6234 produces on its own, how much the AZD9550 combination adds, how the body-composition (fat versus lean) split looks in humans, and whether the promised tolerability advantage - less nausea and vomiting than GLP-1 drugs - actually materializes. Because amylin slows gastric emptying, prescribers will also watch for effects on the absorption of other oral drugs and, in people with diabetes, hypoglycemia risk when amylin agonists are combined with insulin or secretagogues. The bottom line: AZD6234 is a credible, mechanistically sensible entry in the amylin wave, notable for AstraZeneca's decision to develop it hand-in-hand with a GLP-1/glucagon partner - but it remains an experimental, unapproved compound whose human weight-loss data have not yet been shown. This article is educational and not medical advice; AZD6234 is available only through authorized clinical trials. Ready to track your peptide research? Open PepTracker Pro (https://app.peptrackerpro.com/) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. [1] A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone - ClinicalTrials.gov NCT06862791 Source (https://clinicaltrials.gov/study/NCT06862791) 2. [2] A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 (D8460C00004) - AstraZeneca Clinical Trials Source (https://www.astrazenecaclinicaltrials.com/study/D8460C00004/) 3. [3] A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 Is - ClinicalTrials.gov NCT06151964 Source (https://clinicaltrials.gov/study/NCT06151964) 4. [4] 88-OR: Long-Acting Amylin Analog AZD6234 in Combination with the GLP-1R Agonist Semaglutide Enhances Body Weight and Fat Mass Loss in DIO Rats - Diabetes (ADA 2025) Source (https://diabetesjournals.org/diabetes/article/74/Supplement_1/88-OR/159941/88-OR-Long-Acting-Amylin-Analog-AZD6234-in) 5. [5] Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity - PMC Source (https://pmc.ncbi.nlm.nih.gov/articles/PMC12085449/) 6. [6] AZD6234 - AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data - Fierce Biotech Source (https://www.fiercebiotech.com/biotech/astrazeneca-reveals-oral-glp1-scored-phase-2-wins-holds-back-weight-loss-data) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Read full research disclaimer → (https://peptrackerpro.com/research-disclaimer) ## Related Articles research-summaries cover image (https://peptrackerpro.com/blog/petrelintide-amylin-phase2-zupreme-1-tolerability-roche-zealand-ada-2026-june-2026) research-summaries ### Petrelintide and the Amylin Moment: Zealand and Roche's Phase 2 Win on Tolerability Heads to ADA 2026 — June 1, 2026 Peptide Research Update (https://peptrackerpro.com/blog/petrelintide-amylin-phase2-zupreme-1-tolerability-roche-zealand-ada-2026-june-2026) Zealand Pharma and Roche's amylin analog petrelintide delivered up to 10.7% mean weight loss in the Phase 2 ZUPREME-1 trial with GI side effects comparable to placebo - a tolerability-first profile heading to ADA 2026 as the amylin class matures into the next pillar of obesity care. PepTracker Pro Research Team June 1, 2026 8 min read min read Read (https://peptrackerpro.com/blog/petrelintide-amylin-phase2-zupreme-1-tolerability-roche-zealand-ada-2026-june-2026) research-summaries cover image (https://peptrackerpro.com/blog/ada-2026-day2-petrelintide-zupreme1-full-data-da1726-posters-amylin-metabolic-june-2026) research-summaries ### ADA 2026 Day 2: Petrelintide Full ZUPREME-1 Data Confirms Cardiometabolic Benefits and Phase 3 Path, DA-1726 Posts Three Abstracts — June 6, 2026 Peptide Research Update (https://peptrackerpro.com/blog/ada-2026-day2-petrelintide-zupreme1-full-data-da1726-posters-amylin-metabolic-june-2026) ADA 2026 Day 2 in New Orleans brings full ZUPREME-1 body composition and cardiometabolic data for petrelintide (Zealand/Roche) — confirming hsCRP reductions of 17–41%, triglyceride reductions of 12–21%, and waist circumference improvements of up to 10.8 cm, all with placebo-like tolerability — alongside three MetaVia DA-1726 late-breaking poster abstracts covering final MAD data, lean mass preservation, and direct hepatic FibroScan endpoints. PepTracker Pro Research Team June 6, 2026 8 min read min read Read (https://peptrackerpro.com/blog/ada-2026-day2-petrelintide-zupreme1-full-data-da1726-posters-amylin-metabolic-june-2026) Research & Compounds cover image (https://peptrackerpro.com/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) Research & Compounds ### The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026 (https://peptrackerpro.com/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) Amylin has become the obesity field's favorite non-GLP-1 mechanism — but almost every amylin drug is an injection. Structure Therapeutics just started first-in-human testing of ACCG-2671, an oral, once-daily small-molecule amylin agonist. Here's what amylin does, why an oral version matters, how ACCG-2671 compares to amycretin, eloralintide, cagrilintide, and petrelintide, and why 'in a Phase 1 trial' is very different from 'available to buy.' PepTracker Pro Team June 14, 2026 9 min read Read (https://peptrackerpro.com/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "AZD6234: AstraZeneca's Selective Amylin Agonist Bets on a Gentler Path to Weight Loss - and a Partner in AZD9550 (September 21, 2026)", "description": "AZD6234 is AstraZeneca's once-weekly amylin agonist, engineered to trigger fat-selective weight loss with less nausea than GLP-1 drugs - and it's being tested both alone and paired with the GLP-1/glucagon dual agonist AZD9550. Here's what the preclinical and early-clinical data actually show, and where the open questions are.", "datePublished": "2026-09-21", "dateModified": "2026-09-21", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/azd6234-astrazeneca-long-acting-selective-amylin-receptor-agonist-sara-pramlintide-analog-amy3r-obesity-overweight-once-weekly-subcutaneous-azd9550-glp1-glucagon-dual-agonist-combination-factorial-nct06862791-fat-selective-weight-loss-phase-2-september-21-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "AZD6234: AstraZeneca's Selective Amylin Agonist Bets on a Gentler Path to Weight Loss - and a Partner in AZD9550 (September 21, 2026)", "item": "https://peptrackerpro.com/blog/azd6234-astrazeneca-long-acting-selective-amylin-receptor-agonist-sara-pramlintide-analog-amy3r-obesity-overweight-once-weekly-subcutaneous-azd9550-glp1-glucagon-dual-agonist-combination-factorial-nct06862791-fat-selective-weight-loss-phase-2-september-21-2026" } ] } ] ```